<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939770</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0912</org_study_id>
    <secondary_id>NCI-2011-01937</secondary_id>
    <secondary_id>P10666</secondary_id>
    <secondary_id>COG-ADVL0912</secondary_id>
    <secondary_id>CDR0000647587</secondary_id>
    <secondary_id>ADVL0912</secondary_id>
    <secondary_id>ADVL0912</secondary_id>
    <secondary_id>UM1CA097452</secondary_id>
    <nct_id>NCT00939770</nct_id>
    <nct_alias>NCT01182896</nct_alias>
  </id_info>
  <brief_title>Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma</brief_title>
  <official_title>A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well&#xD;
      it works in treating young patients with solid tumors or anaplastic large cell lymphoma that&#xD;
      has returned after a period of improvement or does not respond to treatment. Crizotinib may&#xD;
      stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.&#xD;
      (Phase 1 completed 2/15/13)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose (MTD) and recommend a Phase 2 dose of Crizotinib&#xD;
      administered orally twice daily to children with relapsed/refractory solid tumors and&#xD;
      anaplastic large cell lymphoma (ALCL). (completed 2/15/13) II. To define and describe the&#xD;
      toxicities of Crizotinib administered on this schedule.&#xD;
&#xD;
      III. To characterize the pharmacokinetics of Crizotinib in children with refractory cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the anti-tumor activity of Crizotinib within the confines of a&#xD;
      Phase 1 study. (completed 2/15/13) II. To obtain initial Phase 2 data on the anti-tumor&#xD;
      activity of Crizotinib in children with relapsed/refractory neuroblastoma and ALCL.&#xD;
&#xD;
      III. To preliminarily examine the relationship between anaplastic lymphoma kinase (ALK)&#xD;
      status (e.g, the presence of a mutation, duplication, amplification, and/or translocation) in&#xD;
      patients with neuroblastoma (NB) or ALCL and response to Crizotinib.&#xD;
&#xD;
      IV. To preliminarily examine the relationship between minimal residual disease (MRD) status&#xD;
      and clinical response to Crizotinib in patients with ALCL.&#xD;
&#xD;
      V. To use a questionnaire to gather preliminary information on the palatability of the oral&#xD;
      solution formulation of Crizotinib.&#xD;
&#xD;
      VI. To evaluate for potential alterations in bone growth in pediatric patients.&#xD;
&#xD;
      OUTLINE: This is a phase 1 dose-escalation study (completed 2/15/13) followed by a phase 2&#xD;
      study.&#xD;
&#xD;
      Patients receive crizotinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2009</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib</measure>
    <time_frame>28 days</time_frame>
    <description>The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event (AE) reporting. The MTD/RP2D is defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Toxicities of Crizotinib</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilized for AE reporting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State C Max of Crizotinib</measure>
    <time_frame>Cycle 1 (day 15- 28) pre-dose, 1, 2,4, 6-8 hours post dose</time_frame>
    <description>Mean with standard deviation of peak of serum concentration curve at steady state by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State C Average of Crizotinib</measure>
    <time_frame>Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose</time_frame>
    <description>Mean with standard deviation of average serum concentration curve at steady state by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State AUC of Crizotinib</measure>
    <time_frame>Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose</time_frame>
    <description>Mean with standard deviation of area under the serum concentration curve at steady state by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State Clearance of Crizotinib</measure>
    <time_frame>Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hour post-dose</time_frame>
    <description>Mean with standard deviation of the elimination of crizotinib at steady state by dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Minimum Residual Disease (MRD)</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>MRD status will be reported descriptively. The relationship between MRD status and clinical response to treatment will be examined in children with ALCL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Malignant Solid Neoplasm</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Refractory Anaplastic Large Cell Lymphoma</condition>
  <condition>Refractory Malignant Solid Neoplasm</condition>
  <condition>Refractory Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (crizotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (crizotinib)</arm_group_label>
    <other_name>MET Tyrosine Kinase Inhibitor PF-02341066</other_name>
    <other_name>PF-02341066</other_name>
    <other_name>PF-2341066</other_name>
    <other_name>Xalkori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (crizotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (crizotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (crizotinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving the formulated capsules must have a body surface area (BSA) &gt;= 0.63&#xD;
             m^2 at the time of study enrollment&#xD;
&#xD;
          -  Patients must have had histologic verification of malignancy at original diagnosis or&#xD;
             relapse&#xD;
&#xD;
          -  * Phase 1 (Part A1) - COMPLETE: Patients with relapsed or refractory solid tumors or&#xD;
             anaplastic large cell lymphoma (excluding patients with primary or metastatic central&#xD;
             nervous system [CNS] tumors or patients with primary cutaneous ALCL)&#xD;
&#xD;
          -  * Phase 1 (Part A2) - COMPLETE: Patients with confirmed ALK fusion proteins, ALK&#xD;
             mutations, ALK amplification (defined as greater than 4-fold increase in the ALK&#xD;
             signal number as compared to reference signal number on chromosome 2q arm) or MET&#xD;
             proto-oncogene, receptor tyrosine kinase (MET) mutation or amplification; testing to&#xD;
             confirm the presence of ALK fusion proteins, ALK mutations, ALK amplification or&#xD;
             evidence of MET mutation or amplification for eligibility purposes must be performed&#xD;
             as a Clinical Laboratory Improvement Act (CLIA)-certified assay; ALK&#xD;
             immunohistochemistry can be used as a surrogate for fluorescent in situ hybridization&#xD;
             (FISH) for patients with inflammatory myofibroblastic tumors (IMT) or ALCL&#xD;
&#xD;
          -  ** Note: Evidence for MET mutation or amplification is defined as:&#xD;
&#xD;
               -  Positive for c-Met amplification by FISH; or&#xD;
&#xD;
               -  Positive for known c-Met kinase domain activating mutations including V1110L,&#xD;
                  H1112L, H1112Y, H1124D, M1149T, T1191I, V1206L, L1213V, V1238I, M1268T, P1009S,&#xD;
                  T1010I, R988C, V941L, but excluding Y1248C, Y1248H, Y1248D, and Y1253D; or&#xD;
&#xD;
               -  Chromosomal translocations that lead to altered transcriptional regulation of&#xD;
                  c-Met and/or hepatocyte growth factor (HGF) including metastatic alveolar soft&#xD;
                  part sarcoma, clear cell sarcoma, rhabdomyosarcoma, or translocation associated&#xD;
                  renal cell carcinoma)&#xD;
&#xD;
          -  * Phase 1 (Part A3) - COMPLETE: Patients with relapsed or refractory neuroblastoma,&#xD;
             with or without bone marrow involvement, who are not eligible for Part A1 or A2 or&#xD;
             cannot enroll on Part A1 because of stratum suspension or lack of available slots&#xD;
             (these patients will be enrolled at one dose level below the dose level at which&#xD;
             patients on Part A1 are actively enrolling)&#xD;
&#xD;
          -  * Phase 2 (Part B): Patients with ALK+ relapsed or refractory neuroblastoma&#xD;
&#xD;
          -  * Phase 2 (Part C): Patients with ALK+ relapsed or refractory ALCL (excluding patients&#xD;
             with primary cutaneous ALCL)&#xD;
&#xD;
          -  * Phase 2 (Part A2): Patients with diagnoses other than neuroblastoma or ALCL with&#xD;
             confirmed ALK fusion proteins, ALK mutations, ALK amplification (defined as greater&#xD;
             than 4-fold increase in the ALK signal number as compared to reference signal number&#xD;
             on chromosome 2q arm) or MET mutation or amplification; testing to confirm the&#xD;
             presence of ALK fusion proteins, ALK mutations, ALK amplification or evidence of MET&#xD;
             mutation or amplification for eligibility purposes must be performed as a&#xD;
             CLIA-certified assay; ALK immunohistochemistry can be used as a surrogate for FISH for&#xD;
             patients with IMT&#xD;
&#xD;
          -  Disease status:&#xD;
&#xD;
               -  Phase 1 (Part A): Patients must have either measurable and/or evaluable disease&#xD;
&#xD;
               -  Phase 2 (Part B): Patients with neuroblastoma must have proven ALK+ disease with&#xD;
                  either measurable and/or evaluable disease as indicated below:&#xD;
&#xD;
                    -  Measurable tumor on magnetic resonance imaging (MRI), computed tomography&#xD;
                       (CT) scan or X-ray obtained within 2 weeks prior to study enrollment&#xD;
&#xD;
                    -  Evaluable tumor by meta-iodobenzyl guanidine I 123 (MIBG) scan and/or bone&#xD;
                       marrow involvement with tumor cells seen on routine morphology&#xD;
&#xD;
               -  Phase 2 (Part C): Patients must have proven ALK+ disease with either measurable&#xD;
                  or evaluable disease&#xD;
&#xD;
          -  Performance level: Karnofsky &gt;= 50 for patients &gt; 16 years of age and Lansky &gt;= 50 for&#xD;
             patients =&lt; 16 years of age); Note: patients who are unable to walk because of&#xD;
             paralysis, but who are up in a wheelchair, will be considered ambulatory for the&#xD;
             purpose of assessing the performance score&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             anti-cancer therapy:&#xD;
&#xD;
               -  Myelosuppressive chemotherapy:&#xD;
&#xD;
                    -  Solid tumors: Patients with solid tumors must not have received chemotherapy&#xD;
                       within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)&#xD;
&#xD;
                    -  Lymphoma: Patients with lymphoma who relapse during standard maintenance&#xD;
                       therapy are eligible at time of relapse; for patients with ALCL who relapse&#xD;
                       while they are receiving cytotoxic therapy, at least 14 days must have&#xD;
                       elapsed since the completion of cytotoxic therapy; Note: cytoreduction with&#xD;
                       hydroxyurea can be initiated and continued for up to 24 hours prior to the&#xD;
                       start of Crizotinib&#xD;
&#xD;
          -  At least 7 days since the completion of therapy with a growth factor&#xD;
&#xD;
          -  At least 7 days since the completion of therapy with a biologic agent; for agents that&#xD;
             have known adverse events occurring beyond 7 days after administration, this period&#xD;
             must be extended beyond the time during which adverse events are known to occur; the&#xD;
             duration of this interval must be discussed with the study chair&#xD;
&#xD;
          -  At least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior&#xD;
             treatment with a monoclonal antibody&#xD;
&#xD;
          -  &gt;= 2 weeks (wks) for local palliative radiation therapy (XRT) (small port); &gt;= 6 weeks&#xD;
             must have elapsed since treatment with therapeutic doses of MIBG; &gt;= 6 months must&#xD;
             have elapsed if prior total body irradiation (TBI), craniospinal XRT or &gt;= 50%&#xD;
             radiation of pelvis; &gt;= 6 wks must have elapsed if other substantial bone marrow (BM)&#xD;
             radiation&#xD;
&#xD;
          -  Bone marrow/stem cell transplant or infusion without TBI:&#xD;
&#xD;
               -  Part A1 or Part C: No evidence of active graft vs host disease and &gt;= 3 months&#xD;
                  must have elapsed since stem cell transplant or infusion&#xD;
&#xD;
               -  Part A2, Part A3, or Part B: No evidence of active graft vs host disease and &gt;= 6&#xD;
                  weeks must have elapsed since stem cell transplant or infusion&#xD;
&#xD;
          -  At least 42 days after the completion of any type of immunotherapy, e.g. tumor&#xD;
             vaccines&#xD;
&#xD;
          -  Patients must not have received prior therapy with Crizotinib&#xD;
&#xD;
          -  Patients on Part A1 or Part C of the study:&#xD;
&#xD;
               -  For patients with solid tumors or ALCL without bone marrow involvement:&#xD;
&#xD;
                    -  Peripheral absolute neutrophil count (ANC) &gt;= 1,000/mm^3&#xD;
&#xD;
                    -  Platelet count &gt;= 75,000/mm^3 (transfusion independent, defined as not&#xD;
                       receiving platelet transfusions within a 7 day period prior to enrollment)&#xD;
&#xD;
                    -  Hemoglobin &gt;= 8.0 g/dL (may receive red blood cell [RBC] transfusions)&#xD;
&#xD;
               -  Patients with known bone marrow metastatic disease:&#xD;
&#xD;
                    -  Peripheral absolute neutrophil count (ANC) &gt;= 750/mm^3&#xD;
&#xD;
                    -  Platelet count &gt;= 25,000/mm^3 (may receive platelet transfusions)&#xD;
&#xD;
                    -  Hemoglobin &gt;= 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
                    -  Not known to be refractory to RBC or platelet transfusions Transfusions are&#xD;
                       permitted to meet both the platelet and hemoglobin criteria; Note: patients&#xD;
                       with known bone marrow metastatic disease are not evaluable for&#xD;
                       hematological toxicity for the purposes of dose escalation&#xD;
&#xD;
          -  Patients eligible for Part A2, Part A3, or Part B of the study must meet the&#xD;
             hematologic criteria below for enrollment:&#xD;
&#xD;
               -  Peripheral absolute neutrophil count (ANC) &gt;= 750/mm^3&#xD;
&#xD;
               -  Platelet count &gt;= 25,000/mm^3 (may receive platelet transfusions)&#xD;
&#xD;
               -  Hemoglobin &gt;= 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
               -  Not known to be refractory to red cell or platelet transfusions Transfusions are&#xD;
                  permitted to meet both the platelet and hemoglobin criteria&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70&#xD;
             ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:&#xD;
&#xD;
               -  1 to &lt; 2 years: 0.6 mg/dL&#xD;
&#xD;
               -  2 to &lt; 6 years: 0.8 mg/dL&#xD;
&#xD;
               -  6 to &lt; 10 years: 1 mg/dL&#xD;
&#xD;
               -  10 to &lt; 13 years: 1.2 mg/dL&#xD;
&#xD;
               -  13 to &lt; 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)&#xD;
&#xD;
               -  &gt;= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + unconjugated) =&lt; 1.5 x upper limit of normal (ULN) for&#xD;
             age&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 110&#xD;
             U/L; for the purpose of this study, the ULN for SGPT is 45 U/L&#xD;
&#xD;
          -  Serum albumin &gt;= 2 g/dL&#xD;
&#xD;
          -  Corrected QT interval (QTc) =&lt; 480 msec&#xD;
&#xD;
          -  All patients and/or their parents or legal guardians must sign a written informed&#xD;
             consent; assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines&#xD;
&#xD;
          -  Patients taking the capsule formulation must be able to swallow capsules; feeding tube&#xD;
             administration is allowed for patients receiving the oral solution (OS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests&#xD;
             must be obtained in girls who are post-menarchal; males or females of reproductive&#xD;
             potential may not participate unless they have agreed to use an effective&#xD;
             contraceptive method&#xD;
&#xD;
          -  Patients receiving corticosteroids who have not been on a stable or decreasing dose of&#xD;
             corticosteroid for the prior 7 days are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving another investigational drug are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving other anti-cancer agents, with the exception of&#xD;
             hydroxyurea for patients with ALCL, are not eligible&#xD;
&#xD;
          -  As Crizotinib is an inhibitor of cytochrome P450, family 3, subfamily A, polypeptide 4&#xD;
             (CYP3A4), patients chronically receiving medications known to be metabolized by CYP3A4&#xD;
             and with narrow therapeutic indices including pimozide, aripiprazole, triazolam,&#xD;
             ergotamine and halofantrine are not eligible; the topical use of these medications (if&#xD;
             applicable) is allowed&#xD;
&#xD;
          -  Patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7&#xD;
             days prior to study enrollment, including but not limited to, ketoconazole,&#xD;
             itraconazole, miconazole, clarithromycin, erythromycin, ritonavir, indinavir,&#xD;
             nelfinavir, saquinavir, amprenavir, delavirdine, nefazodone, diltiazem, verapamil, and&#xD;
             grapefruit juice are not eligible; the topical use of these medications (if&#xD;
             applicable), e.g. 2% ketoconazole cream, is allowed&#xD;
&#xD;
          -  Patients chronically receiving drugs that are known potent CYP3A4 inducers within 12&#xD;
             days prior to study enrollment, including but not limited to carbamazepine,&#xD;
             phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir, and St. John's&#xD;
             wort are not eligible; the topical use of these medications (if applicable) is allowed&#xD;
&#xD;
          -  Patients with known interstitial fibrosis or interstitial lung disease are not&#xD;
             eligible&#xD;
&#xD;
          -  Patients with a known history of myocardial infarction or cerebrovascular accident are&#xD;
             not eligible&#xD;
&#xD;
          -  Patients with central nervous system (CNS) tumors or known CNS metastases are not&#xD;
             eligible; patients with a history of CNS metastases that have been surgically resected&#xD;
             are eligible only if the baseline evaluation shows no evidence of current CNS&#xD;
             metastases; patients with any evidence of CNS metastases on baseline evaluation are&#xD;
             not eligible, regardless of whether the lesions have been previously treated and/or&#xD;
             appear stable&#xD;
&#xD;
          -  Patients who have an uncontrolled infection are not eligible&#xD;
&#xD;
          -  Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael P Mosse</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>January 31, 2020</results_first_submitted>
  <results_first_submitted_qc>April 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2020</results_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT00939770/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="P3">
          <title>Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="P4">
          <title>Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="P5">
          <title>Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="P6">
          <title>Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="P7">
          <title>Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID</title>
          <description>Part B: Patients with ALK+ relapsed/refractory neuroblastoma</description>
        </group>
        <group group_id="P8">
          <title>Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID</title>
          <description>Part C: Patients with ALK+ relapsed/refractory ALCL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="37"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="14"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="B2">
          <title>Phase 1:Part A: PF-02341066 130 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="B3">
          <title>Phase 1:Part A: PF-02341066 165 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="B4">
          <title>Phase 1:Part A: PF-02341066 215 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="B5">
          <title>Phase 1: Part A: PF-02341066 280 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="B6">
          <title>Phase 1: Part A: PF-02341066 365 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="B7">
          <title>Phase 2: Part B: PF-02341066 280 mg/m²/Dose BID</title>
          <description>Part B: Patients with ALK+ relapsed/refractory neuroblastoma</description>
        </group>
        <group group_id="B8">
          <title>Phase 2: Part C: PF-02341066 280 mg/m²/Dose BID</title>
          <description>Part C: Patients with ALK+ relapsed/refractory ALCL</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="38"/>
            <count group_id="B6" value="11"/>
            <count group_id="B7" value="14"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="B2" value="12" lower_limit="6" upper_limit="20"/>
                    <measurement group_id="B3" value="8" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="B4" value="11.5" lower_limit="3" upper_limit="20"/>
                    <measurement group_id="B5" value="9" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="B6" value="10" lower_limit="2" upper_limit="20"/>
                    <measurement group_id="B7" value="5.5" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="B8" value="9.5" lower_limit="6" upper_limit="15"/>
                    <measurement group_id="B9" value="9" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib</title>
        <description>The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event (AE) reporting. The MTD/RP2D is defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity.</description>
        <time_frame>28 days</time_frame>
        <population>Phase 1 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Part A</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib</title>
          <description>The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event (AE) reporting. The MTD/RP2D is defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity.</description>
          <population>Phase 1 patients</population>
          <units>mg/m²/dose BID</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Toxicities of Crizotinib</title>
        <description>The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilized for AE reporting.</description>
        <time_frame>Up to 30 days post-treatment</time_frame>
        <population>All patients included in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Part A:PF-02341066 130 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Part A:PF-02341066 165 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Part A:PF-02341066 215 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Part A:PF-02341066 280 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Part A: PF-02341066 365 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O7">
            <title>Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part B: Patients with ALK+ relapsed/refractory neuroblastoma</description>
          </group>
          <group group_id="O8">
            <title>Phase 2:Part C: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part C: Patients with ALK+ relapsed/refractory ALCL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicities of Crizotinib</title>
          <description>The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilized for AE reporting.</description>
          <population>All patients included in analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State C Max of Crizotinib</title>
        <description>Mean with standard deviation of peak of serum concentration curve at steady state by dose level.</description>
        <time_frame>Cycle 1 (day 15- 28) pre-dose, 1, 2,4, 6-8 hours post dose</time_frame>
        <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 3</title>
            <description>PF-02341066 165 mg/m²/dose BID</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 4</title>
            <description>PF-02341066 215 mg/m²/dose BID</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 5</title>
            <description>PF-02341066 280 mg/m²/dose BID</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 6</title>
            <description>PF-02341066 365 mg/m²/dose BID</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State C Max of Crizotinib</title>
          <description>Mean with standard deviation of peak of serum concentration curve at steady state by dose level.</description>
          <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294" spread="0"/>
                    <measurement group_id="O2" value="601" spread="118"/>
                    <measurement group_id="O3" value="717" spread="201"/>
                    <measurement group_id="O4" value="972" spread="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State C Average of Crizotinib</title>
        <description>Mean with standard deviation of average serum concentration curve at steady state by dose level.</description>
        <time_frame>Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose</time_frame>
        <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 3</title>
            <description>PF-02341066 165 mg/m²/dose BID</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 4</title>
            <description>PF-02341066 215 mg/m²/dose BID</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 5</title>
            <description>PF-02341066 280 mg/m²/dose BID</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 6</title>
            <description>PF-02341066 365 mg/m²/dose BID</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State C Average of Crizotinib</title>
          <description>Mean with standard deviation of average serum concentration curve at steady state by dose level.</description>
          <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" spread="0"/>
                    <measurement group_id="O2" value="469" spread="114"/>
                    <measurement group_id="O3" value="582" spread="173"/>
                    <measurement group_id="O4" value="731" spread="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State AUC of Crizotinib</title>
        <description>Mean with standard deviation of area under the serum concentration curve at steady state by dose level.</description>
        <time_frame>Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose</time_frame>
        <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 3</title>
            <description>PF-02341066 165 mg/m²/dose BID</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 4</title>
            <description>PF-02341066 215 mg/m²/dose BID</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 5</title>
            <description>PF-02341066 280 mg/m²/dose BID</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 6</title>
            <description>PF-02341066 365 mg/m²/dose BID</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State AUC of Crizotinib</title>
          <description>Mean with standard deviation of area under the serum concentration curve at steady state by dose level.</description>
          <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose</population>
          <units>ng•h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2950" spread="0"/>
                    <measurement group_id="O2" value="5630" spread="1370"/>
                    <measurement group_id="O3" value="6990" spread="2080"/>
                    <measurement group_id="O4" value="8770" spread="2740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State Clearance of Crizotinib</title>
        <description>Mean with standard deviation of the elimination of crizotinib at steady state by dose level.</description>
        <time_frame>Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hour post-dose</time_frame>
        <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 3</title>
            <description>PF-02341066 165 mg/m²/dose BID</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 4</title>
            <description>PF-02341066 215 mg/m²/dose BID</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 5</title>
            <description>PF-02341066 280 mg/m²/dose BID</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 6</title>
            <description>PF-02341066 365 mg/m²/dose BID</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Clearance of Crizotinib</title>
          <description>Mean with standard deviation of the elimination of crizotinib at steady state by dose level.</description>
          <population>Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose.</population>
          <units>mL/min/m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="735" spread="0"/>
                    <measurement group_id="O2" value="652" spread="159"/>
                    <measurement group_id="O3" value="736" spread="255"/>
                    <measurement group_id="O4" value="731" spread="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Up to 8 years</time_frame>
        <population>Part A Participants with relapsed or refractory solid tumors or anaplastic large cell lymphoma (ALCL)</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <population>Part A Participants with relapsed or refractory solid tumors or anaplastic large cell lymphoma (ALCL)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Up to 8 years</time_frame>
        <population>Part B and Part C participants with relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (ALCL)</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part B: Patients with ALK+ relapsed/refractory neuroblastoma</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part C: Patients with ALK+ relapsed/refractory ALCL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <population>Part B and Part C participants with relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (ALCL)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Minimum Residual Disease (MRD)</title>
        <description>MRD status will be reported descriptively. The relationship between MRD status and clinical response to treatment will be examined in children with ALCL.</description>
        <time_frame>Up to 8 years</time_frame>
        <population>MRD Patients</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID</title>
            <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
          </group>
          <group group_id="O7">
            <title>Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part B: Patients with ALK+ relapsed/refractory neuroblastoma</description>
          </group>
          <group group_id="O8">
            <title>Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID</title>
            <description>Part C: Patients with ALK+ relapsed/refractory ALCL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Minimum Residual Disease (MRD)</title>
          <description>MRD status will be reported descriptively. The relationship between MRD status and clinical response to treatment will be examined in children with ALCL.</description>
          <population>MRD Patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years</time_frame>
      <desc>Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The &quot;AE Other&quot; table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="E2">
          <title>Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="E3">
          <title>Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="E4">
          <title>Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="E5">
          <title>Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="E6">
          <title>Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID</title>
          <description>Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.</description>
        </group>
        <group group_id="E7">
          <title>Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID</title>
          <description>Part B: Patients with ALK+ relapsed/refractory neuroblastoma</description>
        </group>
        <group group_id="E8">
          <title>Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID</title>
          <description>Part C: Patients with ALK+ relapsed/refractory ALCL</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastric fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bone infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infective myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Aortic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abducens nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>IVth nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eyelid function disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flashing lights</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Papilledema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Jejunal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophageal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gum infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood antidiuretic hormone abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Avascular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Unequal limb length</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abducens nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Accessory nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Glossopharyngeal nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>IVth nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Movements involuntary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vagus nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Genital edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Periorbital edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior sponsor approval</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

